1. Laser nanobubbles induce immunogenic cell death in breast cancer
- Author
-
Jessica A. Widman, S. A. Torres-Hurtado, Thomas E. Milner, Laura J. Suggs, Nitesh Katta, Eri Takematsu, Xu Feng, Tania Betancourt, Aaron B. Baker, James W. Tunnell, and Hieu T. M. Nguyen
- Subjects
Technology ,Programmed cell death ,medicine.medical_treatment ,Breast Neoplasms ,Immunogenic Cell Death ,Bioengineering ,02 engineering and technology ,HMGB1 ,Article ,Vaccine Related ,03 medical and health sciences ,Immune system ,Breast Cancer ,medicine ,Humans ,Nanotechnology ,General Materials Science ,HMGB1 Protein ,Nanoscience & Nanotechnology ,030304 developmental biology ,Cancer ,0303 health sciences ,biology ,Chemistry ,Lasers ,Immunotherapy ,021001 nanoscience & nanotechnology ,medicine.disease ,Hsp70 ,Cytoplasm ,Physical Sciences ,Chemical Sciences ,biology.protein ,Cancer research ,Immunogenic cell death ,Immunization ,Generic health relevance ,0210 nano-technology ,Calreticulin - Abstract
Recent advances in immunotherapy have highlighted a need for therapeutics that initiate immunogenic cell death in tumors to stimulate the body’s immune response to cancer. This study examines whether laser-generated bubbles surrounding nanoparticles (“nanobubbles”) induce an immunogenic response for cancer treatment. A single nanosecond laser pulse at 1064 nm generates micron-sized bubbles surrounding gold nanorods in the cytoplasm of breast cancer cells. Cell death occurred in cells treated with nanorods and irradiated but not in cells with irradiation treatment alone. Cells treated with nanorods and irradiation had increased damage-associated molecular patterns (DAMPs), including increased expression of chaperone proteins human high mobility group box 1 (HMGB1), adenosine triphosphate (ATP), and heat shock protein 70 (HSP70). This enhanced expression of DAMPs led to the activation of dendritic cells. Overall, this treatment approach is a rapid and highly specific method to eradicate tumor cells with simultaneous immunogenic cell death signaling, showing potential as a combination strategy for immunotherapy.
- Published
- 2020